In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec Taps Exelixis' Scangos To Be New CEO

Executive Summary

Exelixis’s long-time CEO George Scangos, PhD, is taking the the helm of Biogen Idec. The move is counterintuitive, both for the commercial stage Biogen and for Scangos, whose career has largely been focused on research and early development and free of activist shareholder pressure.
Advertisement

Related Content

Biogen Idec Charts A New Course
Biogen Idec Charts A New Course
The New Oral MS Drugs: The Challenges in Dislodging Biologics
The New Oral MS Drugs: The Challenges in Dislodging Biologics
Symphony's Project Financing Model Adapts
Symphony's Project Financing Model Adapts
End of an Era for GSK and Exelixis
End of an Era for GSK and Exelixis
Takeda/ Millennium: The Price is Right
Takeda/ Millennium: The Price is Right

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003522

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel